The study indicated the long-term effectiveness and safety of InterStim in patients with fecal incontinence of more than twice per week.
At three years, 86 percent of subjects had at least a 50 percent reduction in incontinent episodes and 40 percent had perfect continence.
Read the Diseases of the Colon & Rectum report on InterStim Therapy for incontinence.
Related Articles on Incontinence:
First Artificial Sphincter Could Treat Fecal, Urinary Incontinence
FDA Approves Solesta to Treat Life-Altering Fecal Incontinence
FDA Gastroenterology and Urology Device Panel Approves Fecal Incontinence Product
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
